Margin Execution Drives Better Performance in Quarter and Higher Guidance for Fiscal 2024
Q2 revenue of $5.0 billion increased 4.6% as reported, 4.7% currency-neutral and 5.7% organicQ2 GAAP and.
The technology ensures medications are managed correctly, simplifies workflows and automatically sends vital information like infusion-status data to a patient’s electronic medical record.
Margin Execution Drives Better Performance in Quarter and Higher Guidance for Fiscal 2024
Q1 revenue of $4.7 billion increased 2.6% as reported, 1.6% currency-neutral and 2.4% organicQ1 GAAP and.